Submitted by: Novo Nordisk
Posted: Jun 03, 2015 – 01:00 PM EST
BAGSVAERD, Denmark, Jun. 03 /CSRwire/ - Today, Novo Nordisk published a new issue of its quarterly sustainability magazine, TBL Quarterly with focus on the US. Diabetes affects 29 million people in the US and is changing the health of its citizens and putting pressure on the delivery of healthcare. Making a positive difference for patients and the healthcare system requires partnerships and collaborations with communities and with those who have a stake in how the US confronts diabetes.
The new TBL Quarterly, Collaborating for better care – changing diabetes in the US uncovers the stories of how Novo Nordisk collaborates in the fight against diabetes.
“Novo Nordisk is a diabetes leader in the US, but we cannot continue on top in the same, traditional ‘big pharma’ way,” says Jesper Høiland, executive vice president, Novo Nordisk US. “With the prevalence of diabetes rising each year, we know that making a difference is not something we can do on our own.”
In the new issue of TBL Quarterly, Novo Nordisk maps out some of the current challenges to preventing, diagnosing and improving the treatment of diabetes. Through feature articles and infographics, the company shows how collaborations and partnerships can contribute to better health, including understanding the drivers of urban diabetes in Houston, ensuring diabetes screening reaches people at risk, creating shared value for Novo Nordisk and society, and maximizing the impact of corporate giving.
The TBL Quarterly is published four times a year. If you want to receive notification when new issues are available, send a mail to firstname.lastname@example.org.
About the TBL Quarterly
Novo Nordisk manages its business in accordance with the Triple Bottom Line (TBL) business principle and pursues business solutions that maximise value to both the company and its stakeholders. Through selected themes, new perspectives and personal stories, the TBL Quarterly demonstrates how our TBL business principle supports long-term value creation. The TBL Quarterly is available as a reader-friendly PDF.
About Novo Nordisk
Headquartered in Denmark, Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has also given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity.
Novo Nordisk strives to conduct its activities in a financially, environmentally and socially responsible way. The strategic commitment to corporate sustainability has brought the company onto centre stage as a leading player in today’s business environment, recognised for its integrated reporting, stakeholder engagement and consistently high sustainability performance.
For more information, please contact: